Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01516073 · ClinicalTrials.gov registry record · Phase 2
12-Week Study in Adult Subjects With Asthma
A Phase 2 study of Asthma, sponsored by Dey.
- Completed
- Registry status
- Phase 2
- Development phase
- 629
- Enrollment target
- 1
- Study location
NCT01516073 is a Phase 2 study of Asthma that has completed, run by Dey. The registered enrollment target is 629 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01516073, a Phase 2 study of Asthma, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 629 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a multi-center, randomized, placebo-controlled parallel-group study to evaluate nebulized fluticasone propionate (FP) dose response in adult subjects with partly controlled and uncontrolled asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-blind treatment.
Conditions Studied
Interventions
- DRUG Fluticasone Propionate
Study Locations (1)
South Carolina
- Greenville Pharmaceutical research, Inc. - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01516073
The ClinicalTrials.gov registry entry for NCT01516073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 629 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (60% lower). The listed sponsor is Dey, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Fluticasone Propionate is the first listed.
NCT01516073 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT01516073 about?
NCT01516073 is a clinical study titled "12-Week Study in Adult Subjects With Asthma". This will be a multi-center, randomized, placebo-controlled parallel-group study to evaluate nebulized fluticasone propionate (FP) dose response in adult subjects with partly controlled and uncontrolled asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-bli...
What is the current status of trial NCT01516073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 629 participants. The study started on 2012-03. Estimated completion is 2013-11.
What conditions does trial NCT01516073 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01516073?
The interventions under investigation include: Fluticasone Propionate (DRUG).
Who is sponsoring clinical trial NCT01516073?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01516073 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.